Shionogi & Co. (SGIOY)
(Delayed Data from OTC)
$8.95 USD
+0.10 (1.11%)
Updated Aug 8, 2025 03:53 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Shionogi & Co., Ltd. Unsponsored ADR has a PEG ratio of 2.48 compared to the Medical - Drugs industry's PEG ratio of 1.26.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGIOY 8.95 +0.10(1.11%)
Will SGIOY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGIOY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGIOY
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
SGIOY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Markets: CMS Energy, Chevron, AutoZone in Focus
Shionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock?
Other News for SGIOY
Shionogi & Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
Shionogi (SGIOY) Reports Strong Q1 Financial Results
Shionogi & Co. reports Q1 results
ViiV expands license to produce generic Apretude in low-income countries